Biblio

Author Title [ Type

] Year

Filters: Author is Zecca, Marco [Clear All Filters]

Journal Article

Lougaris V, Le Piane F, Cancrini C, Conti F, Tommasini A, Badolato R, Trizzino A, Zecca M, De Rosa A, Barzaghi F, et al. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment. Ital J Pediatr. 2024;50(1):103.

Rubio-San-Simón A, van Eijkelenburg NKA, Hoogendijk R, Hasle H, Niemeyer CM, Dworzak MN, Zecca M, Lopez-Yurda M, Janssen JM, Huitema ADR, et al. Azacitidine (Vidaza) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015). Paediatr Drugs. 2023.

Cseh A, Galimard J-E, De La Fuente J, Isgrò A, Zecca M, Garwer B, Biffi A, Aljurf M, Sundin M, Belendez C, et al. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. Br J Haematol. 2023.

Toss A, Quarello P, Mascarin M, Banna GLuigi, Zecca M, Cinieri S, Peccatori FAlessandro, Ferrari A. Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group. Curr Oncol Rep. 2022.

Peccatori J, Mastaglio S, Giglio F, Greco R, Crocchiolo R, Patriarca F, Forno B, Deola S, Assanelli A, Stanghellini MTeresa Lup, et al. Clofarabine and Treosulfan as conditioning for matched related and unrelated HSCT: results from the phase II trial "Clo3o". Biol Blood Marrow Transplant. 2019.

Yoshimi A, van den Heuvel-Eibrink MM, Baumann I, Schwarz S, Simonitsch-Klupp I, de Paepe P, Campr V, Kerndrup GBirk, Sullivan MO', Devito R, et al. Comparison of horse and rabbit anti-thymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica. 2013.

Mantelli M, Avanzini MAntonia, Rosti V, Ingo DM, Conforti A, Novara F, Arrigo G, Boni M, Zappatore R, Lenta E, et al. Comprehensive characterization of mesenchymal stromal cells from patients with Fanconi anaemia. Br J Haematol. 2015.

Vegezzi E, Berzero G, Barbetta D, Colombo AAmelia, Borsani O, Bernasconi P, Compagno F, Zecca M, Campanini G, Simoncelli A, et al. Diagnosing acute encephalitis in patients with hematological disorders: caveats and pitfalls. J Neurovirol. 2019.

Locatelli F, Strålin KBelander, Schmid I, Sevilla J, Smith OP, van den Heuvel-Eibrink MM, Zecca M, Zwaan CM, Gaudy A, Patturajan M, et al. Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA-JMML-001 trial. Pediatr Blood Cancer. 2024:e30931.

Boztug H, Sykora K-W, Slatter M, Zecca M, Veys P, Lankester A, Cant A, Skinner R, Wachowiak J, Glogova E, et al. European society for blood and marrow transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with hematological malignancies. Pediatr Blood Cancer. 2015.

Ferrari A, Quarello P, Mascarin M, Milano GM, Tornesello A, Bertolotti M, Spinelli M, Ballotta P, Borghi MRead, Maule M, et al. Evolving Services for Adolescents with Cancer in Italy: Access to Pediatric Oncology Centers and Dedicated Projects. J Adolesc Young Adult Oncol. 2019.

Rodrigues EMillicent, Ardissino G, Pintarelli G, Capone V, Mariotti J, Verna M, Bernardo MEster, Faraci M, Tozzi M, Bucalossi A, et al. Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA. Thromb Haemost. 2021.

Masetti R, Castelli I, Astolfi A, Bertuccio SNicola, Indio V, Togni M, Belotti T, Serravalle S, Tarantino G, Zecca M, et al. Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Oncotarget. 2016.

Masetti R, Leardini D, Muratore E, Fabbrini M, D'Amico F, Zama D, Baccelli F, Gottardi F, Belotti T, Ussowicz M, et al. Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children. Blood. 2023;142(16):1387-1398.

Albert MH, Slatter MA, Gennery AR, Güngör T, Bakunina K, Markovitch B, Hazelaar S, Sirait T, Courteille V, Aiuti A, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis. Blood. 2022.

Giardino S, Eikema D-J, Piepenbroek B, Algeri M, Ayas M, Faraci M, Tbakhi A, Zecca M, Essa M, Neven B, et al. HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties. Am J Hematol. 2024.

Carpenter PA, Kang HJin, Yoo KHee, Zecca M, Cho B, Lucchini G, Nemecek ER, Schultz KR, Stepensky P, Chaudhury S, et al. Ibrutinib treatment of pediatric chronic graft-versus-host disease: primary results from the phase 1/2 iMAGINE study. Transplant Cell Ther. 2022.

Bagnasco F, Caruso S, Andreano A, Valsecchi MGrazia, Jankovic M, Biondi A, Miligi L, Casella C, Terenziani M, Massimino M, et al. Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960-1999 and registered in the Italian Off-Therapy Registry. Eur J Cancer. 2019;110:86-97.

Saglio F, Pagliara D, Zecca M, Balduzzi A, Cattoni A, Prete A, Tambaro FPaolo, Faraci M, Calore E, Locatelli F, et al. Long-term complications after allogeneic hematopoietic stem cell transplantation for pediatric patients with acute leukemia or myelodysplastic syndrome given either a Treosulfan- or a Busulfan-based conditioning regimen: results of an AIEOP (Associazione . Transplant Cell Ther. 2024.

Wehr C, Gennery AR, Lindemans C, Schulz A, Hoenig M, Marks R, Recher M, Gruhn B, Holbro A, Heijnen I, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol. 2015.

Prete A, Lanino E, Saglio F, Biffi A, Calore E, Faraci M, Rondelli R, Favre C, Zecca M, Casazza G, et al. Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Children with High-Risk Neuroblastoma Using a Reduced-Intensity Conditioning Regimen: Results from the AIEOP trial. Transplant Cell Ther. 2024.

De Cicco M, Lagreca I, Basso S, Barozzi P, Muscianisi S, Bianco A, Riva G, Di Vincenzo S, Pulvirenti C, Sapuppo D, et al. Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1) for the Treatment of NPM1-Acute Myeloid Leukemia. Cancers (Basel). 2023;15(10).

Wlodarski MW, Hirabayashi S, Pastor V, Stary J, Hasle H, Masetti R, Dworzak M, Schmugge M, van den Heuvel-Eibrink M, Ussowicz M, et al. Prevalence, clinical characteristics and prognosis of GATA2-related myelodysplastic syndromes (MDS) in children and adolescents. Blood. 2015.

Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Schmid C, Busca A, et al. Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of th. Hemasphere. 2023;7(7):e920.

Sykora K-W, Beier R, Schulz A, Cesaro S, Greil J, Goździk J, Sedlacek P, Bader P, Schulte J, Zecca M, et al. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial. Bone Marrow Transplant. 2023.